OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -91.95 Million SEK | 1.72% |
| 2022 | -90.49 Million SEK | -0.88% |
| 2021 | -89.7 Million SEK | -6.87% |
| 2020 | -83.93 Million SEK | -0.49% |
| 2019 | -83.52 Million SEK | -66.57% |
| 2018 | -50.14 Million SEK | -21.17% |
| 2017 | -41.38 Million SEK | -7.73% |
| 2016 | -38.41 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -12.93 Million SEK | 49.93% |
| 2024 Q2 | -14.45 Million SEK | -18.29% |
| 2023 Q4 | -25.82 Million SEK | -44.18% |
| 2023 FY | -88.94 Million SEK | 1.72% |
| 2023 Q1 | -23.67 Million SEK | -3.74% |
| 2023 Q2 | -19.96 Million SEK | 15.67% |
| 2023 Q3 | -17.91 Million SEK | 10.28% |
| 2022 Q3 | -19.61 Million SEK | 18.69% |
| 2022 Q2 | -24.11 Million SEK | -0.7% |
| 2022 FY | -90.49 Million SEK | -0.88% |
| 2022 Q4 | -22.81 Million SEK | -16.35% |
| 2022 Q1 | -23.95 Million SEK | 3.33% |
| 2021 FY | -89.7 Million SEK | -6.87% |
| 2021 Q4 | -24.77 Million SEK | -50.57% |
| 2021 Q3 | -16.45 Million SEK | 34.6% |
| 2021 Q2 | -25.15 Million SEK | -7.91% |
| 2021 Q1 | -23.31 Million SEK | 5.58% |
| 2020 Q4 | -24.69 Million SEK | -33.51% |
| 2020 Q3 | -18.49 Million SEK | 17.76% |
| 2020 FY | -83.93 Million SEK | -0.49% |
| 2020 Q1 | -18.26 Million SEK | 36.25% |
| 2020 Q2 | -22.48 Million SEK | -23.16% |
| 2019 Q1 | -17.12 Million SEK | -8.71% |
| 2019 FY | -83.52 Million SEK | -66.57% |
| 2019 Q4 | -28.64 Million SEK | -46.02% |
| 2019 Q3 | -19.61 Million SEK | -8.11% |
| 2019 Q2 | -18.14 Million SEK | -5.94% |
| 2018 Q3 | -11.82 Million SEK | -3.89% |
| 2018 Q2 | -11.38 Million SEK | -1.72% |
| 2018 Q1 | -11.18 Million SEK | 0.0% |
| 2018 FY | -50.14 Million SEK | -21.17% |
| 2018 Q4 | -15.75 Million SEK | -33.25% |
| 2017 FY | -41.38 Million SEK | -7.73% |
| 2016 FY | -38.41 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | -18.572% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 130.591% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 130.591% |
| Arcoma AB | 4.66 Million SEK | 2073.305% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 30.301% |
| BICO Group AB (publ) | -618.3 Million SEK | 85.128% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 334.163% |
| CellaVision AB (publ) | 167.05 Million SEK | 155.047% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -39.469% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -210.961% |
| C-Rad AB (publ) | 44.24 Million SEK | 307.838% |
| Duearity AB (publ) | -25.76 Million SEK | -256.93% |
| Dignitana AB (publ) | -15.02 Million SEK | -511.979% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 3.0% |
| Getinge AB (publ) | 3.81 Billion SEK | 102.411% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -34.348% |
| Iconovo AB (publ) | -45.77 Million SEK | -100.879% |
| Integrum AB (publ) | 6.51 Million SEK | 1512.027% |
| Luxbright AB (publ) | -25.8 Million SEK | -256.357% |
| Mentice AB (publ) | -679 Thousand SEK | -13442.857% |
| Paxman AB (publ) | 12.61 Million SEK | 828.711% |
| Promimic AB (publ) | -9.11 Million SEK | -908.511% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 45.49% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -70.481% |
| ScandiDos AB (publ) | -13.48 Million SEK | -582.014% |
| Sectra AB (publ) | 518.49 Million SEK | 117.735% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -40.29% |
| Senzime AB (publ) | -133.74 Million SEK | 31.245% |
| SpectraCure AB (publ) | -21.35 Million SEK | -330.687% |
| Stille AB | 44.95 Million SEK | 304.565% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 97.438% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 338.81% |